NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

Liraglutide的中國市場:2021年∼2025年

Investigation Report on China's Liraglutide Market 2021-2025

出版商 China Research and Intelligence 商品編碼 1009411
出版日期 內容資訊 英文 50 Pages
商品交期: 最快1-2個工作天內
價格
Liraglutide的中國市場:2021年∼2025年 Investigation Report on China's Liraglutide Market 2021-2025
出版日期: 2021年06月04日內容資訊: 英文 50 Pages
簡介

Liraglutide的銷售額,2016年∼2020年年年增加。Liraglutide,2017年納入醫療保險償付目錄。因此,銷售額從2017年的5,198萬人民幣,增加到2018年的1億1,439萬人民幣,年度成長率約120.05%。由於COVID-19傳染病的影響,中國的Liraglutide的銷售額,2020年達了2億8,673萬人民幣,不過,成長率比2019年低,是30.43%。中國的Liraglutide的銷售額的年複合成長率,2016年∼2020年是61.87%。

本報告提供中國的Liraglutide市場相關調查分析,COVID-19的影響,銷售額、銷售數量,價格,市場預測等相關的系統性資訊。

目錄

第1章 Liraglutide的相關概念

  • Liraglutide的適應症
  • 中國的Liraglutide的發展
  • 中國的Liraglutide的政府核准
  • 對中國的Liraglutide銷售的COVID-19的影響

第2章 中國的Liraglutide銷售

  • Liraglutide的銷售額
    • 總銷售額
    • 銷售額:各地區
  • Liraglutide銷售數量
    • 總銷售數量
    • 銷售數量:各地區
  • Liraglutide銷售:中國的各劑型
    • 注射
    • 其他劑型分析

第3章 中國的主要Liraglutide製造商分析

  • 主要的Liraglutide製造商市場佔有率分析
    • 市場佔有率:各銷售額
    • 市場佔有率:銷售各數量
  • Novo Nordisk A/S

第4章 中國的各種製造商Liraglutide的價格

  • Novo Nordisk A/S (VICTOZA)
  • 其他企業分析

第5章 中國的Liraglutide醫藥品市場預測

  • 中國的Liraglutide市場發展的影響要素
  • 市場規模的預測
  • 市場趨勢的預測
目錄
Product Code: 2106510

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, developed by Novo Nordisk A/S. Its product VICTOZA firstly launched in the EU in July 2009 and firstly approved to enter the Chinese market in 2011. Liraglutide is a medication used for the treatment of type 2 diabetes or obesity. As one of the most important GLP-1 receptor agonists, Liraglutide is the only human GLP-1 analog that has been shown to reduce the risk of cardiovascular death. By 2020, Novo Nordisk A/S is the only manufacturer in the Chinese Liraglutide market.

According to CRI's market research, Liraglutide sales have increased year by year from 2016 to 2020. Liraglutide was included in the medical insurance reimbursement catalog in 2017. Therefore, the sales value growth in 2018 was the most obvious, from CNY51.98 million in 2017 to CNY114.39 million in 2018. The annual growth rate is about 120.05%. Due to the impact of the COVID-19 epidemic, the sales value of China's Liraglutide reached CNY286.73 million in 2020 and the growth rate is 30.43%, which is less than that in 2019. The CAGR of Liraglutide's sales value from 2016 to 2020 is 61.87% in China.

CRI expects that the sales value of Liraglutide will have a recovery growth from 2021 to 2025 with the effective alleviation of the COVID-19 epidemic. The patent of Liraglutide has expired, and the drug registration application for Liraglutide injection produced by Shenzhen Hanyu Pharmaceutical Co., Ltd. has been officially accepted in 2019. Since then, the number of manufacturers will gradually increase, the market will continue to expand, and the price will decline, which will cause the increase in sales and sale volume of Liraglutide. In addition, the huge patient population will also enable the Liraglutide market to continue to expand. In China, on average, there is 1 diabetic in 10 adults, and type 2 diabetic patients account for more than 90% of all diabetic patients. The huge number of patients has also increased the demand for Liraglutide. Therefore, its sales will continue to grow as the market expands in the future.

Topics Covered:

  • The impact of COVID-19 on China's Liraglutide market
  • Sales value of China's Liraglutide 2016-2020
  • Competitive landscape of China's Liraglutide market
  • Prices of Liraglutide in China
  • Prices of Liraglutide in China by regions and manufacturers
  • Analysis of factors affecting the development of China's Liraglutide market
  • Prospect of China's Liraglutide market from 2021 to 2025

Table of Contents

1 Relevant Concepts of Liraglutide

  • 1.1 Indications for Liraglutide
  • 1.2 Development of Liraglutide in China
  • 1.3 Governmental Approval of Liraglutide in China
  • 1.4 The Impact of COVID-19 on Liraglutide sales in China

2 Sales of Liraglutide in China, 2016-2020

  • 2.1 Sales Value of Liraglutide
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value by Region
  • 2.2 Sales Volume of Liraglutide
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume by Region
  • 2.3 Sales of Liraglutide by Dosage Form in China, 2016-2020
    • 2.3.1 Injection
    • 2.3.2 Analysis of Other Dosage Forms

3 Analysis of Major Liraglutide Manufacturers in China, 2016-2020

  • 3.1 Analysis of Market Share of Major Liraglutide Manufacturers
    • 3.1.1 Investigation on Market Share by Sales Value
    • 3.1.2 Investigation on Market Share by Sales volume
  • 3.2 Novo Nordisk A/S
    • 3.2.1 Enterprise Profile
    • 3.2.2 Sales of VICTOZA (Novo Nordisk A/S's Liraglutide) in China

4 Prices of Liraglutide for Different Manufacturers in China, 2020-2021

  • 4.1 Novo Nordisk A/S (VICTOZA)
  • 4.2 Analysis of Other Enterprises

5 Prospect of Chinese Liraglutide drug Market, 2021-2025

  • 5.1 Influential Factors of Chinese Liraglutide Market Development
    • 5.1.1 The Impact of COVID-19 on Chinese Liraglutide Market
    • 5.1.2 Market Drivers and Opportunities
    • 5.1.3 Market Threats and Challenges
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend

List of Charts

  • Chart Patent Information About Liraglutide Injection Registration in China
  • Chart Sales Value of Liraglutide Injection over the World
  • Chart Sales Value of Liraglutide Injection in China, 2016-2020
  • Chart Sales Value of Liraglutide Injection in China by Region, 2016-2020
  • Chart Sales Volume of Liraglutide Injection in China, 2016-2020
  • Chart Sales Volume of Liraglutide Injection in China by Region, 2016-2020
  • Chart Market Share by Sales Value of Top Liraglutide Manufacturers in China, 2016-2020
  • Chart Sales Value and Volume of VICTOZA in China, 2016-2020
  • Chart Referential Prices of VICTOZA in China, 2020-2021
  • Chart Forecast on Sales Value of Liraglutide in China, 2021-2025
  • Chart Forecast on Sales Volume of Liraglutide in China, 2021-2025